CClinicalTrials.gg
RecruitingNCT06595459Updated Jun 22, 2026

The Options 2 Study

A Phase 4 interventional study of Nicotine Pouches and Mini Nicotine lozenges in Smoker and Smoking Cessation, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by University of Wisconsin, Madison · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 4 months later.
Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to investigate how well nicotine pouches and nicotine mini lozenges serve as substitutes for cigarettes when people try to switch from smoking to using these alternate nicotine products.

Participants will:

  • Use nicotine pouches, nicotine mini lozenges, or no study product for a week and then try not to smoke for 3 weeks.
  • Have 6 in-person research visits and 1 follow-up call
  • Complete questionnaires at each study contact and use a smartphone app to record smoking and study product use
Read the detailed description

Researchers currently lack critical data needed to appraise the potential for nicotine pouches to benefit public health. Specifically, they do not know how readily smokers will adopt pouches, how effectively they can substitute for cigarettes when smokers are trying to avoid smoking, the role of nicotine dose in the ability of pouches to serve as a substitute, or the mechanisms that facilitate or hinder successful product transition. This study will address these questions using a 4-arm randomized controlled trial of adults who smoke ≥5 cigarettes daily and are not planning to quit smoking in the next 30 days. This study will provide a rigorous evaluation of the potential efficacy of a relatively modified risk new nicotine product as a substitute for combusted cigarettes. The head-to-head comparison with FDA-approved mini lozenges can inform tobacco regulatory policy decisions.

02

Conditions studied

  • Smoker
  • Smoking Cessation

Browse trials for

03

In context

Smoking Cessation

304 studies on the registry are indexed under Smoking Cessation; 139 are open to participants now.

This study's planned enrollment of 300 is above the median of 154 across 285 interventional studies indexed under Smoking Cessation.

Browse Smoking Cessation studies →

Lead sponsor

University of Wisconsin, Madison is the lead sponsor of 1,161 studies on the registry; 182 are open to participants now.

Of its 151 completed or terminated interventional studies of FDA-regulated products, 114 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • ≥ 21 years old (i.e., able to legally purchase tobacco products)
  • able to read and communicate in English
  • no plans to quit smoking in the next 30 days
  • willing to stop using nicotine replacement or varenicline
  • willing to stop using bupropion (i.e., Wellbutrin, Zyban) if they are currently using it only for smoking cessation
  • smoking ≥ 5 cigarettes per day for the past 6 months
  • exhaled carbon monoxide ≥ 6 ppm
  • no nicotine pouch or smokeless tobacco (including snus) use within the last 6 months

Exclusion criteria

Exclusion Criteria:

  • currently in treatment for psychosis or bipolar disorder
  • currently taking bupropion for non-smoking cessation reasons (e.g., Wellbutrin for depression)
  • currently pregnant or breastfeeding
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    3mg Nicotine Pouches

    Participants will use 3mg nicotine pouches

    Drug: Nicotine Pouches

  • Experimental
    6mg Nicotine Pouches

    Participants will use 6mg nicotine pouches

    Drug: Nicotine Pouches

  • Experimental
    Nicotine Mini Lozenges

    Participants will use mini lozenges with dosing based on time to first cigarette (2mg or 4mg)

    Drug: Mini Nicotine lozenges

  • No intervention
    No Study Product

    Participants randomized to this arm will use a mint candy during two different 30-minute laboratory sessions only.

Interventions

  • DrugNicotine Pouches

    nicotine pouches

    Also known as: ZYN

  • DrugMini Nicotine lozenges

    mini lozenges

06

What researchers measure

Primary outcomes

  1. Mean number of cigarettes smoked per day during the 21-day switching period.

    Participants will self-report on their cigarette use

    Time frame: Baseline to 3 weeks

Secondary outcomes

  1. Change in cigarette craving

    Participants will rate their craving for a cigarette using a 0-100 visual analog scale, where 0 = no craving and 100 = extreme craving after sampling their assigned study product after overnight abstinence from smoking

    Time frame: Baseline to 3 weeks

  2. Mean units of study product used per day during the 7-days prior to the switching period

    Participants will report their study product use via EMA

    Time frame: For 7-days leading up to the switching period

  3. Mean units of study product used per day during the 21-day of the switching period

    Participants will report their study product use via EMA

    Time frame: 21-days of the switching period

07

Study locations

1 of 1 sites recruiting
  • University of Wisconsin
    Madison, Wisconsin 53705, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06595459
Lead sponsor
University of Wisconsin, Madison
Collaborators
National Institutes of Health (NIH), National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
May 21, 2025
Primary completion
Jan 1, 2029 (estimated)
Completion
Jul 30, 2029 (estimated)
Last update
Jun 22, 2026

Study contacts

Megan Piper, PhD
Contact
mep@ctri.wisc.edu
608-265-5472
Mark Zehner
Contact
mark.zehner@wisc.edu
608-262-7568
Megan Piper, PhD
principal investigator · University of Wisconsin, Madison

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion